NCT01283373View on ClinicalTrials.gov

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

84

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Prostate Cancer

Interventions

DRUG

DSTP3086S

DSTP3086S administered intravenously

DRUG

DSTP3086S

Escalating intravenous dose

Trial Locations (5)

10065

New York

48201

Detroit

60637

Chicago

94115

San Francisco

98195

Seattle

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY